134 related articles for article (PubMed ID: 26982320)
1. Preformulation Studies on Piperlongumine.
Aodah A; Pavlik A; Karlage K; Myrdal PB
PLoS One; 2016; 11(3):e0151707. PubMed ID: 26982320
[TBL] [Abstract][Full Text] [Related]
2. Piperlongumine (piplartine) as a lead compound for anticancer agents - Synthesis and properties of analogues: A mini-review.
Piska K; Gunia-Krzyżak A; Koczurkiewicz P; Wójcik-Pszczoła K; Pękala E
Eur J Med Chem; 2018 Aug; 156():13-20. PubMed ID: 30006159
[TBL] [Abstract][Full Text] [Related]
3. Preformulation studies of myricetin: a natural antioxidant flavonoid.
Yao Y; Lin G; Xie Y; Ma P; Li G; Meng Q; Wu T
Pharmazie; 2014 Jan; 69(1):19-26. PubMed ID: 24601218
[TBL] [Abstract][Full Text] [Related]
4. Preformulation studies of a novel HIV protease inhibitor, AG1343.
Longer M; Shetty B; Zamansky I; Tyle P
J Pharm Sci; 1995 Sep; 84(9):1090-3. PubMed ID: 8537887
[TBL] [Abstract][Full Text] [Related]
5. Preformulation study of the inclusion complex warfarin-beta-cyclodextrin.
Zingone G; Rubessa F
Int J Pharm; 2005 Mar; 291(1-2):3-10. PubMed ID: 15707726
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of N-heteroaromatic ring-based analogs of piperlongumine as potent anticancer agents.
Zou Y; Yan C; Zhang H; Xu J; Zhang D; Huang Z; Zhang Y
Eur J Med Chem; 2017 Sep; 138():313-319. PubMed ID: 28686911
[TBL] [Abstract][Full Text] [Related]
7. Piperlongumine B and analogs are promising and selective inhibitors for acetylcholinesterase.
Wiemann J; Karasch J; Loesche A; Heller L; Brandt W; Csuk R
Eur J Med Chem; 2017 Oct; 139():222-231. PubMed ID: 28802122
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological activity of piperlongumine derivatives as selective anticancer agents.
Wu Y; Min X; Zhuang C; Li J; Yu Z; Dong G; Yao J; Wang S; Liu Y; Wu S; Zhu S; Sheng C; Wei Y; Zhang H; Zhang W; Miao Z
Eur J Med Chem; 2014 Jul; 82():545-51. PubMed ID: 24937186
[TBL] [Abstract][Full Text] [Related]
9. Piperlongumine is a novel nuclear export inhibitor with potent anticancer activity.
Niu M; Xu X; Shen Y; Yao Y; Qiao J; Zhu F; Zeng L; Liu X; Xu K
Chem Biol Interact; 2015 Jul; 237():66-72. PubMed ID: 26026911
[TBL] [Abstract][Full Text] [Related]
10. Preformulation study of a poorly water-soluble drug, alpha-pentyl-3-(2-quinolinylmethoxy)benzenemethanol: selection of the base for dosage form design.
Serajuddin AT; Sheen PC; Mufson D; Bernstein DF; Augustine MA
J Pharm Sci; 1986 May; 75(5):492-6. PubMed ID: 3735089
[TBL] [Abstract][Full Text] [Related]
11. Novel non-trimethoxylphenyl piperlongumine derivatives selectively kill cancer cells.
Zhang Y; Ma H; Wu Y; Wu Z; Yao Z; Zhang W; Zhuang C; Miao Z
Bioorg Med Chem Lett; 2017 Jun; 27(11):2308-2312. PubMed ID: 28434764
[TBL] [Abstract][Full Text] [Related]
12. Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent.
Tripathi SK; Biswal BK
Pharmacol Res; 2020 Jun; 156():104772. PubMed ID: 32283222
[TBL] [Abstract][Full Text] [Related]
13. Physicochemical characterization and an injection formulation study of water insoluble ZCVI₄-2, a novel NO-donor anticancer compound.
Gao Y; Li L; Zhang J; Su F; Gong Z; Lai Y; Zhang Y
Arch Pharm Res; 2012 Jul; 35(7):1177-86. PubMed ID: 22864740
[TBL] [Abstract][Full Text] [Related]
14. Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide.
Shah JC; Chen JR; Chow D
Pharm Res; 1989 May; 6(5):408-12. PubMed ID: 2748532
[TBL] [Abstract][Full Text] [Related]
15. Overview of piperlongumine analogues and their therapeutic potential.
Zhu P; Qian J; Xu Z; Meng C; Zhu W; Ran F; Zhang W; Zhang Y; Ling Y
Eur J Med Chem; 2021 Aug; 220():113471. PubMed ID: 33930801
[TBL] [Abstract][Full Text] [Related]
16. Long chain lipid based tamoxifen NLC. Part I: preformulation studies, formulation development and physicochemical characterization.
Shete H; Patravale V
Int J Pharm; 2013 Sep; 454(1):573-83. PubMed ID: 23535345
[TBL] [Abstract][Full Text] [Related]
17. Piperlongumine Induces Reactive Oxygen Species (ROS)-Dependent Downregulation of Specificity Protein Transcription Factors.
Karki K; Hedrick E; Kasiappan R; Jin UH; Safe S
Cancer Prev Res (Phila); 2017 Aug; 10(8):467-477. PubMed ID: 28673967
[TBL] [Abstract][Full Text] [Related]
18. Piperlongumine induces ROS mediated apoptosis by transcriptional regulation of SMAD4/P21/P53 genes and synergizes with doxorubicin in osteosarcoma cells.
Rawat L; Nayak V
Chem Biol Interact; 2022 Feb; 354():109832. PubMed ID: 35085581
[TBL] [Abstract][Full Text] [Related]
19. Design of acid-responsive polymeric nanoparticles for 7,3',4'-trihydroxyisoflavone topical administration.
Huang PH; Hu SC; Lee CW; Yeh AC; Tseng CH; Yen FL
Int J Nanomedicine; 2016; 11():1615-27. PubMed ID: 27143883
[TBL] [Abstract][Full Text] [Related]
20. Piperlongumine as anticancer agent: The story so far about killing many birds with one stone.
Farooqi AA; Attar R; Yaylim I; Qureshi MZ; Todorovska M; Karatoprak GŞ; Najafi S; Sabitaliyevich UY; Zhenisovna TG; De Sousa DP; Lin X
Cell Mol Biol (Noisy-le-grand); 2018 Aug; 64(11):102-107. PubMed ID: 30213297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
